Literature DB >> 29475733

Decoy-Based, Targeted Inhibition of STAT3: A New Step forward for B Cell Lymphoma Immunotherapy.

Mario M Soldevilla1, Fernando Pastor2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29475733      PMCID： PMC5911647          DOI： 10.1016/j.ymthe.2018.02.006

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  24 in total

1.  Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia.

Authors:  Clive S Zent; Brian J Smith; Zuhair K Ballas; James E Wooldridge; Brian K Link; Timothy G Call; Tait D Shanafelt; Deborah A Bowen; Neil E Kay; Thomas E Witzig; George J Weiner
Journal:  Leuk Lymphoma       Date:  2011-09-19

2.  TLR9-Targeted SiRNA Delivery In Vivo.

Authors:  Dewan Md Sakib Hossain; Dayson Moreira; Qifang Zhang; Sergey Nechaev; Piotr Swiderski; Marcin Kortylewski
Journal:  Methods Mol Biol       Date:  2016

3.  TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.

Authors:  Dewan M S Hossain; Sumanta K Pal; Dayson Moreira; Priyanka Duttagupta; Qifang Zhang; Haejung Won; Jeremy Jones; Massimo D'Apuzzo; Stephen Forman; Marcin Kortylewski
Journal:  Clin Cancer Res       Date:  2015-05-12       Impact factor: 12.531

Review 4.  CpG DNA as a vaccine adjuvant.

Authors:  Christian Bode; Gan Zhao; Folkert Steinhagen; Takeshi Kinjo; Dennis M Klinman
Journal:  Expert Rev Vaccines       Date:  2011-04       Impact factor: 5.217

5.  TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo.

Authors:  Qifang Zhang; Dewan Md Sakib Hossain; Sergey Nechaev; Anna Kozlowska; Wang Zhang; Yong Liu; Claudia M Kowolik; Piotr Swiderski; John J Rossi; Stephen Forman; Sumanta Pal; Ravi Bhatia; Andrew Raubitschek; Hua Yu; Marcin Kortylewski
Journal:  Blood       Date:  2013-01-03       Impact factor: 22.113

Review 6.  Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.

Authors:  Panagiotis Tsirigotis; Bipin N Savani; Arnon Nagler
Journal:  Ann Med       Date:  2016-05-25       Impact factor: 4.709

7.  Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy.

Authors:  Marcin Kortylewski; Maciej Kujawski; Andreas Herrmann; Chunmei Yang; Lin Wang; Yong Liu; Rosalba Salcedo; Hua Yu
Journal:  Cancer Res       Date:  2009-03-03       Impact factor: 12.701

8.  Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies.

Authors:  A L Wong; R A Soo; D S Tan; S C Lee; J S Lim; P C Marban; L R Kong; Y J Lee; L Z Wang; W L Thuya; R Soong; M Q Yee; T M Chin; M T Cordero; B R Asuncion; B Pang; S Pervaiz; J L Hirpara; A Sinha; W W Xu; M Yuasa; T Tsunoda; M Motoyama; T Yamauchi; B C Goh
Journal:  Ann Oncol       Date:  2015-01-21       Impact factor: 32.976

9.  In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses.

Authors:  Marcin Kortylewski; Piotr Swiderski; Andreas Herrmann; Lin Wang; Claudia Kowolik; Maciej Kujawski; Heehyoung Lee; Anna Scuto; Yong Liu; Chunmei Yang; Jiehui Deng; Harris S Soifer; Andrew Raubitschek; Stephen Forman; John J Rossi; Drew M Pardoll; Richard Jove; Hua Yu
Journal:  Nat Biotechnol       Date:  2009-09-13       Impact factor: 54.908

10.  Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies.

Authors:  Michinori Ogura; Toshiki Uchida; Yasuhito Terui; Fumihiko Hayakawa; Yukio Kobayashi; Masafumi Taniwaki; Yasushi Takamatsu; Tomoki Naoe; Kensei Tobinai; Wataru Munakata; Takeshi Yamauchi; Akiko Kageyama; Miyuki Yuasa; Masaaki Motoyama; Takeshi Tsunoda; Kiyohiko Hatake
Journal:  Cancer Sci       Date:  2015-05-25       Impact factor: 6.716
View more
  1 in total

Review 1.  Reciprocal Regulation of Hippo and WBP2 Signalling-Implications in Cancer Therapy.

Authors:  Yvonne Xinyi Lim; Hexian Lin; Sock Hong Seah; Yoon Pin Lim
Journal:  Cells       Date:  2021-11-11       Impact factor: 6.600
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.